The management of cardiovascular disease risk in patients with rheumatoid arthritis. (24th May 2022)

• Record Type: Journal Article
• Authors: Ahmed, Omar; Krishnamurthy, Vinodh; Kaba, Riyaz A; Tahir, Hasan
• Is Part Of: Expert opinion on pharmacotherapy. Volume 23:Number 8(2022)
• Page Start: 947
• Page End: 958
• Publication Date: 2022-05-24
• Subjects: Cardiovascular Risk -- Rheumatoid Arthritis -- DMARD; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2022.2076594
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Rheumatoid Arthritis (RA) is a chronic inflammatory disorder associated with an increased incidence and prevalence of cardiovascular disease (CVD), including myocardial infarction and heart failure. In addition to traditional risk factors, evidence suggests inflammation is critical to the pathophysiology of both conditions. Despite the association being well-recognised, challenges remain in managing cardiovascular risk in RA. Areas Covered: This manuscript analyses the association between CVD and RA and explores the limitations in evaluating cardiovascular risk in RA with available risk assessment tools. The authors review the optimal management of traditional risk factors such as hypertension and dyslipidaemia and contemporary risk factors such as inflammation and analyse the cardiovascular impact of RA medications. Expert opinion: Analysis points to the critical role of inflammation in the pathogenesis of RA and CVD. It is well established that conventional disease-modifying anti-rheumatic drugs (DMARDs) improve cardiovascular outcomes; however, underlying risk often remains underappreciated. The authors suggest there remains an opportunity to improve mortality and morbidity with the early recognition and of at-risk populations and the timely initiation of appropriate cardiovascular and anti-inflammatory medications. More research is necessary into the role that imaging may play in stratifying risk and in the longer-term cardiovascular impact of biological DMARDs.